Compile Data Set for Download or QSAR
Report error Found 60 Enz. Inhib. hit(s) with all data for entry = 11243
TargetDelta-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602180(US11643436, Compound TM-1)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602180(US11643436, Compound TM-1)
Affinity DataEC50:  0.0980nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602189(US11643436, Compound TM-26)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetDelta-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602189(US11643436, Compound TM-26)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602189(US11643436, Compound TM-26)
Affinity DataEC50:  0.00800nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602188(US11643436, Compound TM-22B)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetDelta-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602188(US11643436, Compound TM-22B)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602188(US11643436, Compound TM-22B)
Affinity DataEC50:  0.00900nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602187(US11643436, Compound TM-13A)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetDelta-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602187(US11643436, Compound TM-13A)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602187(US11643436, Compound TM-13A)
Affinity DataEC50:  0.0950nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602186(US11643436, Compound TM-9A)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetDelta-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602186(US11643436, Compound TM-9A)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602186(US11643436, Compound TM-9A)
Affinity DataEC50:  0.00100nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602185(US11643436, Compound TM-8)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetDelta-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602185(US11643436, Compound TM-8)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602184(US11643436, Compound TM-7)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602185(US11643436, Compound TM-8)
Affinity DataEC50:  0.0850nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602180(US11643436, Compound TM-1)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602181(US11643436, Compound TM-2A)
Affinity DataEC50:  0.0330nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetDelta-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602181(US11643436, Compound TM-2A)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602181(US11643436, Compound TM-2A)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602182(US11643436, Compound TM-3)
Affinity DataEC50:  0.0550nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetDelta-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602182(US11643436, Compound TM-3)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602182(US11643436, Compound TM-3)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602183(US11643436, Compound TM-5)
Affinity DataEC50:  0.0270nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetDelta-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602183(US11643436, Compound TM-5)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602183(US11643436, Compound TM-5)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602184(US11643436, Compound TM-7)
Affinity DataEC50:  0.00900nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetDelta-type opioid receptor(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602184(US11643436, Compound TM-7)
Affinity DataEC50: >1.00E+4nMAssay Description:Forskolin can stimulate the release of cAMP from HEK293 cells with high expression of human κ (or μ, or δ)-opioid receptors. The κ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602186(US11643436, Compound TM-9A)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602186(US11643436, Compound TM-9A)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602186(US11643436, Compound TM-9A)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602186(US11643436, Compound TM-9A)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602186(US11643436, Compound TM-9A)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602188(US11643436, Compound TM-22B)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602188(US11643436, Compound TM-22B)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602188(US11643436, Compound TM-22B)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602188(US11643436, Compound TM-22B)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602188(US11643436, Compound TM-22B)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602189(US11643436, Compound TM-26)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602189(US11643436, Compound TM-26)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602189(US11643436, Compound TM-26)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602189(US11643436, Compound TM-26)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602189(US11643436, Compound TM-26)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602185(US11643436, Compound TM-8)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602185(US11643436, Compound TM-8)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602185(US11643436, Compound TM-8)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602185(US11643436, Compound TM-8)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Chengdu Sintanovo Biotechnology

US Patent
LigandPNGBDBM602185(US11643436, Compound TM-8)
Affinity DataIC50: 5.00E+4nMAssay Description:The human liver microsomes (0.253 mg/mL protein) containing cytochrome P450, test compounds (0.05-50 μM), CYPs substrates (10 μM p-acetamin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 60 total ) | Next | Last >>
Jump to: